ArticleJournal of bioenergetics and biomembranes2025
Dimethyl fumarate improves sepsis-induced acute lung injury by inhibiting STING-mediated ferroptosis.
Article in Journal of bioenergetics and biomembranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- GSTP1 as a novel protective target in sepsis: evidence from proteome-wide Mendelian randomization and multi-omics analyses.BMC infectious diseases · 2026Article
- Dimethyl Fumarate vs. Monomethyl Fumarate: Unresolved Pharmacologic Issues.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precise pathogenic mechanisms underlying sepsis-induced acute respiratory distress syndrome (ARDS) remain incompletely characterized. Emerging evidence implicates ferroptosis of alveolar epithelial cells in ARDS pathogenesis, though the regulatory networks governing this association require further elucidation. Stimulator of interferon genes (STING), conventionally recognized as a pivotal mediator of innate immunity through DNA-sensing pathways, has recently been linked to ferroptosis. This investigation elucidates the pulmonary protective mechanisms of DMF in sepsis-induced ALI models. Experimental data revealed elevated ferroptotic activity, inflammatory markers, and oxidative stress in lungs following cecal ligation and puncture (CLP) procedures. DMF administration significantly attenuated pulmonary ferroptosis while concurrently mitigating inflammation and oxidative damage, ultimately ameliorating histological lung injury. Complementary in vitro studies demonstrated DMF's capacity to suppress lipopolysaccharide (LPS)-induced ferroptosis in MLE-12 cells. Mechanistic analyses identified dual protective pathways. DMF not only inhibited LPS-triggered STING activation and subsequent proinflammatory cytokine production but also prevented STING-mediated autophagic degradation of glutathione peroxidase 4 (GPX4). This dual action effectively reduced reactive oxygen species (ROS) accumulation and ferroptotic cell death. These findings position DMF as a promising therapeutic candidate with dual pharmacological actions - functioning as both a STING pathway inhibitor and ferroptosis suppressor.
Indexed as
Identifiers
40616736What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.